: Recall of batches manufactured using active ingredients sourced from NECTAR LIFE SCIENCES LIMITED
2025-11-05Product Description :
|
الاسم التجاري |
الاسم العلمي |
رقم التسجيل |
رقم التشغيلة المتأثرة |
الشركة الصانعة |
||||||||||
|
Trade Name |
Scientific Name |
Register Number |
Affected batch number |
Manufacturer |
||||||||||
|
Cefuzime 500 mg FCT |
CEFUROXIME AXETIL |
1809222615 |
08483 |
09379 |
09886 |
09885 |
08481 |
Gulf Pharmaceutical Industries (Julphar) |
||||||
|
Cefuzime 500 MG TAB |
CEFUROXIME AXETIL |
0210222682 |
08490 |
08759 08476 |
09683 08479 |
09684 08478 |
08488 08477 |
|||||||
|
TRIAXONE 500MG VIAL I.V+5MLWATER FOR INJ |
CEFTRIAXONE |
2510211227 |
3AZ133
|
Tabuk Pharmaceutical Manufacturing Company |
||||||||||
|
TRIAXONE 1GM VIAL I.V +10ML WATER FOR INJ |
CEFTRIAXONE |
46-277-98 |
3AY1421 |
3AY1420 |
3AY1419 |
|||||||||
|
TRIAXONE 1GM VIAL I.M+5ML SOLV.LIDOCAINE |
CEFTRIAXONE |
45-277-98 |
3AQ951 |
3AQ948 |
3AQ937 |
|||||||||
|
WINEX 100MG\5ML ORAL SUSP |
CEFIXIME |
2605257458 |
5BK1429 4BK1330 4BK1395 5BK1425 |
4BK1298 4BK1359 4BK1363 4BK1423 |
3BK1276 4BK1343 4BK1362 4BK1422 |
|||||||||
|
WINEX 200MG CAP |
CEFIXIME |
2510211228 |
3BG187 |
|||||||||||
|
ZINOXIMOR 250 MG F.C.TAB |
Cefuroxime Axetil |
2510222796 |
3AS478 4AS479 4AS480 |
2AS459 3AS477 |
||||||||||
|
ZINOXIMOR 500MG F.C.TABLET |
Cefuroxime Axetil |
0801233062 |
3CA865 3CA866 3CA868 4CA869 4CA870 |
3CA815 3CA860 3CA862 3CA863 3CA864 |
||||||||||
|
EMDITIL 500MG Film-coated TABLET |
CEFUROXIME AXETIL |
1506222215 |
6230934 6231082 6231086 6240946 6240953 6240957 6241206 |
6230933 6230937 6231085 6240945 6240952 6240956 6241205 |
6230932 6230936 6231084 6240944 6240951 6240955 6241204 6241207 |
6230931 6230935 6231083 6240943 6240947 6240954 6240958 6241208 |
Pharma International Co. |
|||||||
Issue :
The SFDA has issued a recall of batches manufactured using active ingredients sourced from NECTAR LIFE SCIENCES LIMITED. It has been determined that NECTAR LIFE SCIENCES LIMITED failed to comply with Good Manufacturing Practices (GMP), which may affect the safety and quality of products manufactured using active ingredients from this manufacturer.
Recommendations :
For healthcare professionals: Stop dispensing the affected batches immediately. Embargo/Quarantine all remaining stock. Affected batches should be returned to the supplier.
For patients,
- Consult your healthcare provider prior to discontinuing use of the affected batches, or for any health concerns.
- Contact the recalling firm or SFDA if you have any questions about the recall.
- Adverse reactions or quality problems experienced with the use of this product may be reported to Saudi Vigilance either online or call center (Call 19999).
